GeneDx Holdings Corp.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $427.5M | $305.5M | $202.6M | $234.7M | $212.2M | $179.3M | $196.2M |
| Cost of Revenue | $129.4M | $111.1M | $112.6M | $261.4M | $228.8M | $175.3M | $113.4M |
| Gross Profit | $298.2M | $194.4M | $90.0M | $-26.8M | $-16.6M | $4.0M | $82.8M |
| Gross Margin | 69.7% | 63.6% | 44.4% | -11.4% | -7.8% | 2.2% | 42.2% |
| Operating Expenses | |||||||
| Research & Development | $72.0M | $45.7M | $58.3M | $86.2M | $105.2M | $72.7M | $34.9M |
| SG&A Expense | $150.8M | $104.5M | $139.0M | $216.2M | $206.0M | $100.7M | $29.5M |
| Operating Income | $-13.1M | $-23.2M | $-180.6M | $-667.7M | $-446.1M | $-242.0M | $-30.4M |
| Operating Margin | -3.1% | -7.6% | -89.2% | -284.5% | -210.3% | -134.9% | -15.5% |
| Interest Expense | — | — | — | $3.2M | $2.8M | $2.5M | $783.0K |
| Pretax Income | $-21.1M | $-52.6M | $-176.7M | $-598.0M | $-245.4M | $-241.3M | $-29.7M |
| Income Tax Expense | $-116.0K | $-343.0K | $-926.0K | $-49.1M | $0 | $0 | $0 |
| Net Income | $-21.0M | $-52.3M | $-175.8M | $-549.0M | $-245.4M | $-241.3M | $-29.7M |
| Net Margin | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | -134.6% | -15.1% |
| EPS (Basic) | $-0.73 | $-1.94 | $-7.23 | $-26.82 | $-1.14 | $-23,518.00 | $-6.27 |
| EPS (Diluted) | $-0.73 | $-1.94 | $-7.23 | $-26.82 | $-1.14 | $-23,518.00 | $-6.27 |
| Shares Outstanding (Basic) | 28.6M | 26.9M | 24.3M | 20.5M | 216.2M | 10.3K | 5.2M |
| Shares Outstanding (Diluted) | 28.6M | 26.9M | 24.3M | 20.5M | 216.2M | 10.3K | 5.2M |
| Dividends Per Share | — | — | — | — | — | — | — |